Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Malar J · 2013 · PMC3582548 · PMID 23342996

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significantp = 0.0510so close (0.05 < p ≤ 0.1)

No statistical model is fitted between Kenya and US studies since the baseline antibody values are significantly different. For the US study, a longitudinally borderline significant difference in geometric mean of ELISA titres between the two dosage groups (p = 0.0510) was observed.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.